Penumbra, Inc.

PEN Healthcare Medical Devices

Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024.

Revenue
+15.6%
EPS
−8.29%
Free cash flow
−37.2%
Total debt
−10.3%

Quarter to September 2026, against a year earlier

319.20 1.91 −0.59%
Market cap
$12.7B
P/E
80.3×
Fwd P/E
68.7×
Dividend yield
—
F-score
8/9
Altman Z
20.17
Beneish M
−2.48
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26
ROE

+8 more TTM periods

13.78% 12.73% 11.37% 10.67%
Piotroski F-Score
8 7 6 6
ROA
10.58% 9.80% 8.80% 8.33%
ROIC
13.09% 13.32% 13.13% 12.73%
Return on Tangible Assets
15.44% 14.28% 12.77% 12.09%
Average Days of Receivables
49.41 46.00 46.18 45.67
Free Cash Flow per Share
4.49 5.42 5.49 5.08
Free Cash Flow
174.93 212.73 215.91 200.29
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026